| Literature DB >> 35774221 |
Dena Abd El Aziz El Sammak1, Hala M Allam2, Rabab M Abdelhay1.
Abstract
Purpose: In many healthcare settings in developing nations, multislice computed tomography (MSCT) imaging may be the only available diagnostic modality for patients with suspected COVID-19 infection, due to a shortage of laboratory kits. This study aimed to evaluate the diagnostic performance and interobserver variability of CO-RADS (COVID-19 Reporting and Data System) in the triage of patients with suspected COVID-19 infection in Zagazig University Hospital. Material and methods: This study included 2500 patients with suspected COVID-19 infection, mean age 60.61 years ± 13.89. 61.4% were male. Unstable patients requiring urgent invasive ventilation, acute coronary syndrome patients, pregnant females, and patients with RT-PCR results available prior to MSCT were excluded from this study. RT-PCR was performed in all patients included in the study.Entities:
Keywords: CO-RADS; COVID-19; MSCT; RT-PCR; triage
Year: 2022 PMID: 35774221 PMCID: PMC9215304 DOI: 10.5114/pjr.2022.117052
Source DB: PubMed Journal: Pol J Radiol ISSN: 1733-134X
Typical features for pulmonary involvement of COVID-19 [16]
| Obligatory features: |
| • Ground-glass opacities, with or without consolidations, in lung regions close to visceral pleural surfaces, including the fissures (subpleural sparing is allowed) |
| • Multifocal bilateral distribution |
| Confirmatory patterns: |
| • Ground-glass regions: |
| - unsharp demarcation, (half) rounded shape |
| - sharp demarcation, outlining the shape of multiple adjacent secondary pulmonary lobules |
| • Crazy paving |
| • Patterns compatible with organizing pneumonia |
| • Thickened vessels within parenchymal abnormalities found in all confirmatory patterns |
Diagnostic performance of CO-RADS in 2500 patients
| First scenario: | ||||||||||||||
| COVID-19 (CO-RADS 4 + CO-RADS 5) vs. no COVID-19 (CO-RADS 1 + CO-RADS 2 + CO-RADS 3) | ||||||||||||||
|
|
| Total | ||||||||||||
|
|
| |||||||||||||
| First scenario | COVID-19 | 829 | 50 | 879 | ||||||||||
| No COVID-19 | 671 | 950 | 1621 | |||||||||||
| Total | 1500 | 1000 | 2500 | |||||||||||
|
|
|
| ||||||||||||
| Sensitivity | 55.27% | 52.71% to 57.80% | ||||||||||||
| Specificity | 95.00% | 93.46% to 96.27% | ||||||||||||
| PPV | 94.31% | 92.65% to 95.62% | ||||||||||||
| NPV | 58.61% | 57.19% to 60.01% | ||||||||||||
| Accuracy | 71.16% | 69.34% to 72.93% | ||||||||||||
| Second scenario: | ||||||||||||||
| COVID-19 (CO-RADS 3 + CO-RADS 4 + CO-RADS 5) vs. no COVID-19 (CO-RADS 1 + CO-RADS 2) | ||||||||||||||
|
|
|
| ||||||||||||
|
|
| |||||||||||||
| Second scenario | COVID-19 | 1249 | 350 | 1599 | ||||||||||
| No COVID-19 | 251 | 650 | 901 | |||||||||||
| Total | 1500 | 1000 | 2500 | |||||||||||
|
|
|
| ||||||||||||
| Sensitivity | 83.27% | 81.28% to 85.12% | ||||||||||||
| Specificity | 65.00% | 61.95% to 67.96% | ||||||||||||
| PPV | 78.11% | 76.58% to 79.57% | ||||||||||||
| NPV | 72.14% | 69.63% to 74.52% | ||||||||||||
| Accuracy | 75.96% | 74.24 % to 77.62% | ||||||||||||
Baseline characteristics of 2500 included patients
| Parameters | Data |
|---|---|
| Age (years); mean ± SD | 18-95; 60.61 ± 13.89 |
| Sex, | |
| Males | 1535 (61.4) |
| Females | 965 (38.6) |
| Symptoms at presentation, | |
| Fever | 2004 (80.2) |
| Tiredness | 90 (3.6) |
| Dry cough | 1300 (52.0) |
| Dyspnoea | 1080 (43.2) |
| Abdominal symptoms | 500 (20.0) |
| IQR (interquartile range), days | 2-10 |
| Number of RT-PCR assays, | |
| 1 | 2050 (82) |
| 2 | 200 (8) |
| 3 | 250 (10) |
| Comorbidities, | |
| Hypertension | 385 (15.4) |
| Obesity | 230 (9.2) |
| Diabetes | 450 (18.0) |
| Cardiovascular disease | 684 (27.4) |
| Chronic lung disease | 570 (22.8) |
| Immune deficiency | 60 (2.4) |
| Cancer | 96 (3.8) |
| Chronic kidney disease | 120 (4.8) |
Patterns of pulmonary involvement on multislice computed tomography (MSCT) images in 2500 patients
| MSCT findings | +ve RT-PCR | –ve RT-PCR | |
|---|---|---|---|
| Bilateral involvement | 1000 | 200 | < 0.001* |
| Peripheral distribution | 1370 | 210 | < 0.001* |
| Posterior involvement | 985 | 100 | < 0.001* |
| Multifocal involvement | 1060 | 115 | < 0.001* |
| Consolidation | 102 | 710 | < 0.001* |
| Pleural effusion | 95 | 100 | 0.796 |
| Reversed halo | 60 | 67 | 0.712 |
| Ground glass opacity | 1249 | 350 | < 0.001* |
| Vascular enlargement | 800 | 50 | < 0.001* |
| Crazy paving | 775 | 20 | < 0.001* |
| Reticulations | 240 | 249 | 0.788 |
Statistically significant.
Association between RT-PCR and CO-RADS
| CO-RADS | Positive RT-PCR | % | Negative RT-PCR | % |
|---|---|---|---|---|
| 1 | 51 | 3.4 | 290 | 29.0 |
| 2 | 200 | 13.3 | 360 | 36.0 |
| 3 | 420 | 28.0 | 300 | 30.0 |
| 4 | 229 | 15.3 | 40 | 4.0 |
| 5 | 600 | 40.0 | 10 | 1.0 |
| Total | 1500 | 100.0 | 1000 | 100.0 |
Inter-observer variability of CO-RADS
| A | Team 2 | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CO-RADS 1 | CO-RADS 2 | CO-RADS 3 | CO-RADS 4 | CO-RADS 5 | |||||
| Team 1 | CO-RADS 1 | Count | 341.0 | 0 | 0 | 0 | 0 | 341.0 | |
| % of total | 13.6 | 0 | 0 | 0 | 0 | 13.6 | |||
| CO-RADS 2 | Count | 20.0 | 540.0 | 0 | 0 | 0 | 560.0 | ||
| % of total | 0.8 | 21.6 | 0 | 0 | 0 | 22.4 | |||
| CO-RADS 3 | Count | 0 | 59.0 | 485.0 | 176.0 | 0 | 720.0 | ||
| % of total | 0 | 2.4 | 19.4 | 7.0 | 0 | 28.8 | |||
| CO-RADS 4 | Count | 0 | 0 | 0 | 255.0 | 14.0 | 269.0 | ||
| % of total | 0 | 0 | 0 | 10.2 | 0.6 | 10.8 | |||
| CO-RADS 5 | Count | 0 | 0 | 0 | 0 | 610.0 | 610.0 | ||
| % of total | 0 | 0 | 0 | 0 | 24.4 | 24.4 | |||
| Total | Count | 361.0 | 599.0 | 485.0 | 431.0 | 624.0 | 2500.0 | ||
| % of total | 14.4 | 23.9 | 19.4 | 17.2 | 24.9 | 100.0 | |||
Green cells represent concordance; purple cells represent discordance
| B | χ2 tests | |||
|---|---|---|---|---|
| Value | df | Asymptotic significance (2-sided) | ||
| McNemar-Bowker test | 269.000 | 4 | < 0.001 | |
| Number of valid cases | 2500 | |||
| C | Symmetric measures | Value | Asymptotic standard errora | Approximately Tb | Asymptotic significance |
|---|---|---|---|---|---|
| Measure of agreement, κ | 0.846 | 0.009 | 74.600 | 0.000 | |
| Number of valid cases | 2500 |
Not assuming the null hypothesis. bUsing the asymptotic standard error assuming the null hypothesis